ライフサイエンスコーパス: Pfizer

1 % of patients seroconverted (26.6% AZ, 22.8% Pfizer).

2 and 593 after second dose (346 AZ versus 247 Pfizer).

3 ter immunization with an mRNA-based vaccine (Pfizer).

4 R)) (latanoprost 0.005% ophthalmic solution, Pfizer).

5 nonclassical cannabinoids was synthesized by Pfizer.

6 ealth Research Board Ireland, GSK/Aspen, and Pfizer.

7 ulfone PF5081090 (1) originally developed by Pfizer.

8 tional Institutes of Health, Merck KGaA, and Pfizer.

9 nal Institute of Health Research (NIHR), and Pfizer.

10 nadian Cancer Society Research Institute and Pfizer.

11 er Immunotherapy, Wyeth Pharmaceuticals, and Pfizer.

12 Foundation, UK Medical Research Council, and Pfizer.

13 o Nordisk, Bayer HealthCare, [corrected] and Pfizer.

14 RNA-1273 [Moderna], and 2 received BNT162b2 [Pfizer]).

15 were responders, comparable between BNT162b2/Pfizer (113 out of 133) and mRNA-1273/Moderna (14 out of

16 PRIMARY FUNDING SOURCE: Penn-Pfizer Alliance and American Heart Association.

17 Merck, Pfizer, American Cancer Society, and Sylvester Comprehen

18 tional and standard doses of AstraZeneca and Pfizer among CoronaVac-primed or AstraZeneca-primed part

19 than CoronaVac-primed participants following Pfizer and AstraZeneca boosters.

20 Pfizer and Bausch & Lomb had the most drops per bottle (

21 % of COVID-19 cases of Sinopharm, Sputnik V, Pfizer and Covishield recipients, respectively, required

22 e more likely to evaluate the mRNA vaccines (Pfizer and Moderna) unacceptable.

23 Pfizer and National Cancer Institute grant to the Childr

24 diary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (proph

25 or off-label uses of gabapentin sponsored by Pfizer and Parke-Davis, and documents were obtained thro

26 which internal documents were available from Pfizer and Parke-Davis; of these trials, 12 were reporte

27 practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (her

28 titute and ECOG-ACRIN Cancer Research Group, Pfizer, and Bayer.

29 Merck Sharp and Dohme, Napp Pharmaceuticals, Pfizer, and Celltrion.

30 National Institutes of Health, BASF, Pfizer, and DSM Nutritional Products.

31 nce Armstrong Foundation, Roche Diagnostics, Pfizer, and Novartis.

32 Cancer Research UK, Amgen, Pfizer, and Roche.

33 ith its dam having received PregSure(R) BVD (Pfizer Animal Health) vaccination prior to the birth of

34 ates targeting SARS-CoV-2 M(pro) designed by Pfizer are under clinical trials, no SARS-CoV-2 medicati

35 British Heart Foundation, Pfizer, AstraZeneca, Schering-Plough, National Institute

36 are lower for fractional than standard dose Pfizer at 28 days (binding IgG geometric mean ratio: 0.7

37 Washington University-Pfizer Biomedical Collaborative.

38 ndividuals receiving vaccinations (BNT162b2 [Pfizer BioNTech] in 1297 [77.3%] and mRNA-1273 [Moderna]

39 in 150 days of receipt of the second dose of Pfizer-BioNTech (67%; 95% CI, 40% to 82%) and Moderna (7

40 aZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people ha

41 ions among some individuals who received the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine discourage p

42 ccination with either Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccine in a cohort of S

43 before and after study participants received Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA-b

44 eers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-2(1-

45 Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to th

46 oderna (RVE, 77.0%; 95% CI, 75.7%-78.2%) and Pfizer-BioNTech (RVE, 72.3%; 95% CI, 70.6%-73.8%).

47 logical responses wane, a single dose of the Pfizer-BioNTech 162b vaccine is associated with an antib

48 second dose was 33% (95% CI, -2% to 56%) for Pfizer-BioNTech and 77% (95% CI, 48% to 91%) for Moderna

49 virus disease 2019 (COVID-19) mRNA vaccines (Pfizer-BioNTech and Moderna) has been increasingly repor

50 e 2019 (COVID-19) pandemic, 2 mRNA vaccines (Pfizer-BioNTech and Moderna) received emergency use auth

51 BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most co

52 events were reported by 1.04% and 2.09% for Pfizer-BioNTech and Oxford-AstraZeneca vaccines, respect

53 main COVID-19 vaccines used in Saudi Arabia (Pfizer-BioNTech and Oxford-AstraZeneca) using telemedici

54 eriod mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273).

55 least 2 doses of mRNA COVID-19 vaccines (ie, Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273) or inacti

56 SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody respo

57 45 individuals had received two doses of the Pfizer-BioNTech BNT162b2 vaccine with a delayed booster

58 RS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCO

59 during the 22- to 42-day risk window for the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 biva

60 ults aged 65 years or older who received the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 biva

61 390 respondents who simultaneously received Pfizer-BioNTech booster and influenza vaccines and 21 02

62 om them 2 weeks following the second dose of Pfizer-BioNTech COVID-19 vaccine.

63 uenza vaccination or after the first dose of Pfizer-BioNTech COVID-19 vaccine.

64 and nine months after the second dose of the Pfizer-BioNTech COVID-19 vaccine.

65 owing the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (internat

66 lthy volunteers who were vaccinated with the Pfizer-BioNTech mRNA vaccine (BNT162b2).

67 ("COVID-19") and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protectio

68 lly following booster immunizations with the Pfizer-BioNTech or Moderna mRNA vaccines.

69 y adults, who received a booster dose of the Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 an

70 No association was found between the Pfizer-BioNTech or Moderna vaccine and severe cardiovasc

71 ination with a messenger RNA (mRNA) vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized w

72 8 individuals, 7 days after receiving either Pfizer-BioNTech or Oxford-AstraZeneca vaccines during Ju

73 prior medically attended COVID-19 diagnoses, Pfizer-BioNTech provided an added benefit for 120 days,

74 Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compar

75 13 109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses), and 2738 the O

76 icant association was identified between the Pfizer-BioNTech vaccine and GBS incidence RR: 0.99 (95%

77 st booster dose (n = 46), (B) CoronaVac with Pfizer-BioNTech vaccine as the first booster dose (n = 5

78 Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant

79 For the Pfizer-BioNTech vaccine, there were 7.20 cases per milli

80 r advantage of delaying the second dose with Pfizer-BioNTech vaccines in reducing infections, unless

81 COVID-19 vaccine from Pfizer-BioNTech was administered in our outpatient clini

82 tion who received 1 single dose of BNT162b2 (Pfizer-BioNTech) (n = 120) and SARS-CoV-2-naive individu

83 (Moderna) (n = 172) or 2 doses of BNT162b2 (Pfizer-BioNTech) (n = 135).

84 of 2 doses of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech) against COVID-19 was high in pediatric

85 evaluated; 69.6% received BNT162b2 vaccine (Pfizer-BioNTech) and 30.3% received mRNA-1273 (Moderna).

86 to assess the effectiveness of the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca

87 dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing i

88 ed-cohort studies in Qatar for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines.

89 19 vaccination with mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)) and adenovirus

90 w technology mRNA vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), and nonreplica

91 Data on mRNA vaccines-BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)-and 1 viral vec

92 162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) and sudden sensorineural hearing loss (

93 se of 5x10(10) virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 mug.

94 primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) breakthrough infections, and mRNA-1273

95 doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021.

96 BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.

97 ta on BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) effectiveness and safety in pregnancy a

98 tive immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical mitigation tool aga

99 In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we

100 ho had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least

101 Administration of a BNT162b2 booster dose (Pfizer-BioNTech) to fully vaccinated individuals aged 60

102 dose of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) to persons 60 years of age or older, th

103 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vacc

104 ter doses of Oxford-AstraZeneca or BNT162b2 (Pfizer-BioNTech) vaccine.

105 to the Oxford-AstraZeneca (AZ) and BNT162b2 (Pfizer-BioNTech) vaccines are limited.

106 e testing, single-dose BNT162b2 vaccination (Pfizer-BioNTech) was associated with -2.4 mean log10 low

107 over time following vaccination by BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), ChAdOx1 (Oxford-A

108 Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccin

109 aZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a n

110 and receipt of a first or second dose of the Pfizer-BioNTech, mRNA-1273 (Moderna), Ad26.COV2.S (Janss

111 or Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech.

112 or Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech.

113 Compared with individuals vaccinated with Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaV

114 d to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer-BioNTech; hereafter referred to as BNT) at a 4-we

115 1.5 vaccine, either through mRNA (Moderna or Pfizer-BioNTech; participants 1, 2, and 3) or adjuvanted

116 or Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age >=65 years was 52.2% for J

117 or Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age 65 years was 52.2% for Jan

118 mRNA-based SARS-CoV-2 vaccination (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) were identified

119 with emergency use authorization (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna], or Ad26.COV2.S [J

120 ng the full-length SARS-CoV-2 spike protein (Pfizer/BioNTech BNT162b2), elicits protective mucosal im

121 cific immune responses to Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S, and Novav

122 nal mRNA therapy utilized in the Moderna and Pfizer/BioNTech COVID-19 vaccines).

123 mistry platforms utilized in the Moderna and Pfizer/BioNTech COVID-19 vaccines.

124 0.09 for those vaccinated with one dose (of Pfizer/BioNTech or Johnson & Johnson).

125 samples from individuals vaccinated with the Pfizer/BioNTech or Moderna mRNA vaccines, we measured ne

126 mong 22 978 880 first-dose recipients of the Pfizer/BioNTech vaccine compared with 22 978 880 first-d

127 sponse developed after administration of the Pfizer/BioNTech vaccine in 124 health care professionals

128 wer first vs second-dose efficacy (e.g., the Pfizer/BioNTech vaccine).

129 vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines.

130 ne followed by a third dose of mRNA vaccine (Pfizer/BioNTech) among healthcare workers (HCWs).

131 ipants received 2 doses of BNT162b2 vaccine (Pfizer/BioNTech) and completed the study.

132 tion with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologou

133 n/Johnson & Johnson) to mRNA-based BNT162b2 (Pfizer/BioNTech) in a contemporary cohort of patients on

134 cipants (0.3%) after 1 dose of the BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccine, 27 of 1

135 Moderna) vaccine compared with the BNT162b2 (Pfizer/BioNTech) vaccine (53.74 [95% CI, 40.49-71.33] ar

136 ine, the Omicron BA.4/BA.5-adapted bivalent (Pfizer/BioNTech) vaccine, or both.

137 f Schwaz/Austria, 100,000 doses of BNT162b2 (Pfizer/BioNTech) were procured to mass vaccinate the ent

138 o 0.30 for those vaccinated with 2 doses (of Pfizer/BioNTech), and from 0.51 to 0.09 for those vaccin

139 03,960 adults): AstraZeneca (AZ/Covishield), Pfizer/BioNtech, Sinopharm and Sputnik V.

140 g 2 321 366 veterans who received 2 doses of Pfizer BNT-162b2 or Moderna mRNA-1273 vaccine by 30 Apri

141 nd saliva samples from groups of vaccinated (Pfizer BNT-162b2), infected and uninfected individuals a

142 It showed substantial but incomplete Pfizer BNT162b2 escape, weak neutralization by self-plas

143 om South African individuals vaccinated with Pfizer BNT162b2.

144 scents and adults 1 month after the two-dose Pfizer (BNT162b2) vaccination.

145 individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior t

146 Finally, three doses of Pfizer/BNT162b2 mRNA vaccination elicit high neutralizat

147 ants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7- to 8-fold less poten

148 m of the COVID-19 virus and the mRNA26 based Pfizer/BNT162b2 vaccines are widely distributed.

149 BMS, Pfizer, Boehringer Ingelheim, Roche Diagnostics.

150 NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foun

151 esearch, Canadian Anesthesiologists Society, Pfizer Canada, Italian Ministry of Health, Fonds NutsOhr

152 search, Canadian Anesthesiologists' Society, Pfizer Canada, Italian Ministry of Heath, Fonds NutsOhra

153 AstraZeneca, Boehringer Ingelheim (Canada), Pfizer (Canada), MSD, Chest, Heart and Stroke Scotland,

154 Canadian Cancer Society Research Institute, Pfizer, Canadian Institutes of Health Research.

155 Results from a retrospective analysis of 32 Pfizer CNS clinical drug candidates are described.

156 Astellas Pharma Inc, Medivation LLC (a Pfizer Company).

157 the assay in a high-throughput screen of the Pfizer compound collection to identify inhibitors of 5-L

158 The Pfizer compound CP-31398 has been reported to stabilize

159 oside (AICAR) and inhibition by caffeine and Pfizer compound CP-91149, which bind to GP at distinct s

160 The Pfizer compound library was screened against the catalyt

161 tection was studied on 26 compounds from the Pfizer compound library, representing a diverse set of s

162 to the Omicron variant after 2 doses of the Pfizer COVID-19 mRNA vaccine.

163 er SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines.

164 oss-lagged design (wave 1 following a second Pfizer dose, wave 2 after their booster).

165 tructurally diverse model compounds from the Pfizer drug library, including ingliforib, furosemide an

166 bb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals

167 U.S. Department of Veterans Affairs and the Pfizer Foundation.

168 micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 in

169 edical Center, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

170 arhus University Research Foundation, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Wellcome Trus

171 rce, Canadian Institutes of Health Research, Pfizer Global Medical Grants, and St.

172 smoking cessation drug varenicline (Chantix; Pfizer, Groton, CT), an alpha4beta2-targeted agonist tha

173 Pfizer had the highest yearly cost at $1198 (P < .001),

174 esponse to these limitations, researchers at Pfizer have now developed the second-generation M(pro) i

175 o the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compa

176 Millennium Inc, Pfizer Inc, Multiple Myeloma Research Foundation, and th

177 funded as investigator initiated research by Pfizer Inc, New York, NY, USA.

178 Pfizer Inc, V Foundation for Cancer Research.

179 Novartis Pharmaceuticals and Pfizer Inc.

180 ologically related to gabapentin (Neurontin; Pfizer Inc., New York, NY).

181 4CMenB (Bexsero; GSK) and rLP2086 (Trumenba; Pfizer, Inc.) vaccine manufacturers.

182 ning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses.

183 aboratories Inc.], and latanoprost [Xalatan; Pfizer, Inc., New York, NY]).

184 gand bioassay response-data (BARD) using 155 Pfizer internal BioPrint assays.

185 Pfizer, International Breast Cancer Study Group, and US

186 -RDB protein IgG) after one and two BNT162b2/Pfizer jabs in residents with and without prior COVID-19

187 Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Networ

188 Exposures were doses 1-3 of the Pfizer, Moderna, AstraZeneca, and Janssen COVID-19 vacci

189 Here, using the Mason-Pfizer monkey retrovirus dUTPase, we study the dUTPase-c

190 nstitutive transport element of simian/Mason-Pfizer monkey retroviruses and the RNA transport element

191 omprised almost entirely of the CTE of Mason-Pfizer monkey virus (CTE RNA) is exported efficiently fr

192 membrane assembly, PPPY L domain) and Mason-Pfizer monkey virus (cytoplasmic assembly, PPPY L domain

193 pp16 proteins of the type D retrovirus Mason-Pfizer monkey virus (M-PMV) are phosphoproteins that are

194 unodeficiency virus type 1 (HIV-1) and Mason-Pfizer monkey virus (M-PMV) but not Moloney murine leuke

195 Mason-Pfizer monkey virus (M-PMV) capsids that have assembled

196 Mason-Pfizer monkey virus (M-PMV) encodes a transmembrane (TM)

197 Mason-Pfizer monkey virus (M-PMV) encodes a transmembrane glyc

198 High Five cells expressing wild-type Mason-Pfizer monkey virus (M-PMV) Gag precursors accumulate as

199 The Mason-Pfizer monkey virus (M-PMV) Gag protein possesses the ab

200 ived protein of the related retrovirus Mason-Pfizer monkey virus (M-PMV) has previously been reported

201 Mason-Pfizer monkey virus (M-PMV) is a prototypical betaretrov

202 The Mason-Pfizer monkey virus (M-PMV) is the prototype of the type

203 a cellular factor regulating HIV-1 and Mason-Pfizer monkey virus (M-PMV) particle release.

204 lycoprotein incorporation into budding Mason-Pfizer monkey virus (M-PMV) particles and abrogate infec

205 tructures and membrane affinity of the Mason-Pfizer monkey virus (M-PMV) wild-type MA with its two bu

206 We sought to determine whether or not Mason-Pfizer monkey virus (M-PMV), a prototype betaretrovirus

207 ontrast, several retroviruses, such as Mason-Pfizer monkey virus (M-PMV), assemble in the cytoplasm i

208 of the prototypical type D retrovirus, Mason-Pfizer monkey virus (M-PMV), can assemble in a cell-free

209 he assembled Gag lattices of HIV-1 and Mason-Pfizer monkey virus (M-PMV), the C-terminal domain of CA

210 Mason-Pfizer monkey virus (M-PMV), the prototype type D retrov

211 Mason-Pfizer monkey virus (M-PMV), the prototypical type D ret

212 "Simple" retroviruses, such as Mason-Pfizer monkey virus (MPMV) and murine leukemia virus (ML

213 egulatory element (PRE)-containing and Mason-Pfizer monkey virus (MPMV) constitutive transport elemen

214 nv expression vectors that contain the Mason-Pfizer monkey virus (MPMV) constitutive transport elemen

215 ther a Rev response element (RRE) or a Mason-Pfizer monkey virus (MPMV) constitutive transport elemen

216 t the genome of the simpler retrovirus Mason-Pfizer monkey virus (MPMV) contains an element that serv

217 t the 5' long terminal repeat (LTR) of Mason-Pfizer monkey virus (MPMV) facilitates Rev/Rev-responsiv

218 Here, we demonstrate that Mason-Pfizer monkey virus (MPMV) is resistant to inhibition by

219 as a nonlentiviral retrovirus such as Mason-Pfizer monkey virus (MPMV), and vice versa.

220 onstitutive transport element (CTE) of Mason-Pfizer monkey virus (MPMV), or the pre-mRNA processing e

221 ociation of KIF-4 with Gag proteins of Mason-Pfizer monkey virus (MPMV), simian immunodeficiency viru

222 stitutive transport element (CTE) from Mason-Pfizer monkey virus (MPMV).

223 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus (MPMV)] and discuss structural featu

224 ing and retention signal CTRS found in Mason-Pfizer monkey virus and that FV Gag has the inherent abi

225 llular capsid transport and release of Mason-Pfizer monkey virus are dependent on myristylation of th

226 d release of murine leukemia virus and Mason-Pfizer monkey virus are insensitive to TSG-5'.

227 ag protein shells-immature capsids--of Mason-Pfizer monkey virus assembled in Escherichia coli from t

228 nscriptional enhancer element from the Mason-Pfizer monkey virus can override the silencing and promo

229 the constitutive transport element of Mason-Pfizer monkey virus can substitute for RRE and Rev at le

230 on of cis-acting elements, such as the Mason-Pfizer monkey virus constitutive transport element (CTE)

231 clear export of mRNAs that contain the Mason-Pfizer monkey virus constitutive transport element (CTE)

232 Tap interacts directly with the Mason-Pfizer monkey virus constitutive transport element (CTE)

233 DeltaCAN had no significant affect on Mason-Pfizer monkey virus constitutive transport element (MPMV

234 either Rev/Rev response element or the Mason-Pfizer monkey virus constitutive transport element.

235 The transmembrane protein of Mason-Pfizer monkey virus contains two heptad repeats that are

236 e transport element (CTE) derived from Mason-Pfizer monkey virus for expression of the viral proteins

237 Unlike most retroviruses, the Mason-Pfizer monkey virus Gag polyproteins assemble into immat

238 SRV-2 and Mason-Pfizer monkey virus have highly homologous elements, whi

239 a unique experimental system in which Mason-Pfizer monkey virus immature capsids are removed from th

240 Mason-Pfizer monkey virus immature capsids selected from the c

241 sarcoma virus IN, rather than HIV-1 or Mason-Pfizer monkey virus IN, were substituted into the struct

242 ntly in the distal zinc knuckle of the Mason-Pfizer monkey virus nucleocapsid protein.

243 For example, Mason-Pfizer monkey virus overcomes cellular restrictions by u

244 export of RNA transcripts derived from Mason-Pfizer monkey virus that contain the constitutive transp

245 ses (HIV-1, murine leukemia virus, and Mason-Pfizer monkey virus), two hepadnaviruses (hepatitis B vi

246 different from that seen in HIV-1 and Mason-Pfizer monkey virus, illustrating further structural div

247 In Mason-Pfizer monkey virus, the required RNA sequence element i

248 ates the CA and NC domains, whereas in Mason-Pfizer monkey virus, this region is densely packed, thus

249 was required for efficient release of Mason-Pfizer monkey virus, which buds primarily by using a PPX

250 of unspliced RNA containing either the Mason-Pfizer monkey virus-CTE or the recently discovered Tap-C

251 ase by a distantly related retrovirus, Mason-Pfizer monkey virus.

252 that interacts with the Gag protein of Mason-Pfizer monkey virus.

253 ho received a 2-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, and (2) previously infecte

254 II) in the absence (control) or presence of Pfizer MTP inhibitor CP-10447 (CP).

255 -Provera (depot medroxyprogesterone acetate; Pfizer, New York City, New York, USA) and, perhaps, low-

256 The Tecnis Z9000 IOL (Pfizer, New York) has been designed with a modified prol

257 The Tecnis Z9000 intraocular lens (IOL) (Pfizer, New York) is the first foldable IOL designed to

258 eated with the p38 MAPK inhibitor PHA666859 (Pfizer, New York, NY) and untreated-and compared with ag

259 mercial preparation of latanoprost (Xalatan; Pfizer, New York, NY) in monkey eyes with laser-induced

260 ataracts in participants not taking Centrum (Pfizer, New York, NY) multivitamins.

261 Sildenafil (Viagra; Pfizer, New York, NY), a selective phosphodiesterase typ

262 Cancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Counc

263 (OR = 1.383; 95% CI, 1.122-1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple

264 alysis responded after two doses of BNT162b2/Pfizer or mRNA-1273/Moderna vaccine, suggesting the shor

265 l antibodies, and vaccination with BNT162b2 (Pfizer) or adenovirus vector vaccines versus messenger R

266 Z seroconverted compared with 130 (52.6%) of Pfizer (P = 0.02; hazard ratio, 1.48; 95% confidence int

267 Four hundred ninety-five AZ and 141 Pfizer patients had a sample analyzed after first dose a

268 tal Health Institute, Eli Lilly and Company, Pfizer Pharmaceuticals, and the Edwin S Webster Foundati

269 syncytial virus (RSV) prefusion F (RSVpreF [Pfizer]) protein subunit vaccine was newly approved and

270 n RSV prefusion F maternal vaccine (RSVpreF [Pfizer, Puurs, Belgium]) for administration to pregnant

271 Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and

272 ), and for Moderna's mRNA-1273 compared with Pfizer's BNT162b2 vaccine (OR = 0.66; 95% CI, 0.62 to 0.

273 Pfizer's branded lantanoprost, Xalatan (New York, New Yo

274 ase Control and Prevention (CDC) recommended Pfizer's COVID-19 messenger RNA (mRNA) vaccine for child

275 ts in their first RSV season: nirsevimab and Pfizer's maternal RSV vaccine.

276 An X-ray-based fragment screen of Pfizer's proprietary fragment collection has resulted in

277 tor, candoxatrilat (8 and 80 microg/kg/min) (Pfizer, Sandwich United Kingdom).

278 = 50) who had received either the Moderna or Pfizer SARS-CoV-2 mRNA vaccine between 2 weeks and 6 mon

279 ological confirmation was obtained using the Pfizer serotype-specific urinary antigen detection tests

280 as tested by using an antagonist, CJ-12,255 (Pfizer), that blocks the binding of SP to the neurokinin

281 Zeneca, Bristol Myers Squibb, Genentech, and Pfizer through the Foundation for the National Institute

282 e used the small molecule compound CP-31398 (Pfizer) to restore wild-type p53 function to the codon 2

283 serotype distribution studies that used both Pfizer UADs (UAD1, detects PCV13 serotypes; UAD2, detect

284 ondon School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bil

285 Pfizer, UK National Institute for Health Research Biomed

286 -2) main protease (M(pro)), was developed by Pfizer under intense pressure during the pandemic to tre

287 edicinal agent pregabalin (commercialized by Pfizer under the trade name Lyrica) is also presented.

288 trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level long

289 ntibody levels are lower in AZ compared with Pfizer vaccinated recipients following 2 vaccine doses.

290 as compared to 91% of those who received the Pfizer vaccine (p = 0.0009).

291 ccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2.

292 A third dose of Pfizer vaccine elicited substantially higher neutralizat

293 vels following vaccination with the BioNTech/Pfizer vaccine was demonstrated with serial self-collect

294 o be comparably immunogenic to the BNT162b2 (Pfizer) vaccine in macaques.

295 of myocarditis after receiving the BNT162b2 (Pfizer) vaccine.

296 he first-approved COVID-19 vaccine (BioNTech/Pfizer), we found key patent filings for the technology

297 ntaining ACC inhibitors recently reported by Pfizer were metabolized in vivo by ketone reduction, whi

298 lfonylurea core such as MCC950 (developed by Pfizer) were discovered by phenotypic screening, however

299 rabbits (n=8; candoxatril, 30 mg/kg per day, Pfizer) were euthanized after 8 weeks of feeding.

300 Initially, mainstream news linked mostly "Pfizer" with side effects (e.g. "allergy", "reaction", "